Could stem cells slow ALS? new trial results are in
NCT ID NCT04745299
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tested a stem cell treatment called Lenzumestrocel in 123 people with ALS. The treatment uses the patient's own bone marrow stem cells and is given alongside the standard drug Riluzole. The goal was to see if it could slow the disease and improve survival and function. Results are being analyzed to determine if this approach offers real benefits.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lenzumestrocel (stem cells from the patient's own bone marrow)
What this could lead to
If it works, this could slow the progression of ALS and help patients maintain function longer.
What could go wrong
This is a single Phase 3 trial with 123 participants. Results may not apply to everyone, and stem cell treatments carry risks like infection or immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hanyang university hospital
Seoul, Seoul, 04763, South Korea
-
Korea University Anam Hospital
Seoul, 02841, South Korea
-
Pusan National University Yangsan Hospital
Yangsan, Kyungsangnam-do, 50612, South Korea
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Seoul National University Hospital
Seoul, South Korea